A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer

被引:0
|
作者
Wang, Xueqing [1 ]
Wang, Guoqing [1 ]
Hao, Yueyue [1 ]
Xu, Yinhong [1 ]
Zhang, Lihua [1 ]
机构
[1] Southeast Univ, Dept Pathol, Zhongda Hosp, Nanjing 210009, Peoples R China
关键词
NSCLC; cytology; EGFR mutation; immunohistochemistry; SENSITIVE DETECTION; L858R MUTATION; EXON; 21; ANTIBODIES; ADENOCARCINOMA; IMMUNOHISTOCHEMISTRY; E746-A750; DELETION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have compared mutation analysis by Amplification Refractory Mutation System (ARMS) and epidermal growth factor receptor (EGFR) mutant-specific antibodies for their ability to detect two common activating EGFR mutations in a cohort of 115 advanced non-small cell lung cancer (NSCLC), including cytology material, core biopsy, and bronchoscopic biopsies. Assessment of EGFR mutation status was performed by using antibodies and ARMS assay specific to the two major forms of mutant EGFR, exon 19 deletion E746-A750 (c.2235_2249del15 or c.2236_2250del15, p.Glu746_Ala750 del) and exon 21 L858R point mutation (c.2573T>G, p.Leu858Arg). In this study the optimal buffer for antigen retrieval was sodium citrate (pH 6.0). Q score was used to evaluate the specific mutant EGFR proteins expression. Validation using clinical material showed deletions in exon 19 were detected in 19.1% and L858R mutation in 20% of all cases by ARMS assay. A cutoff value of score 1 was used as positive by IHC. No wild type cases were immuno-reactive. The antibodies performed well in cytology, core biopsies and bronchoscopic biopsies. There were only one false positive case using L858R IHC (sensitivity 100%, specificity 98.5%, positive predictive value 96%, negative predictive value 100%). All 23 E746-A750 exon 19 deletions identified by mutation analysis were positive by IHC. The sensitivity of exon 19 IHC for E746-A750 was 100%, specificity 100%, positive predictive value 100% and negative predictive value 100%. The result of the IHC stains was finely correlated with mutations status determined by ARMS assay. Although inferior to molecular genetic analysis of the EGFR gene, IHC is highly specific and sensitive for the targeted EGFR mutations. The antibodies are likely to be of clinical value in cases especially where limited tumor material is available, or in situations where molecular genetic analysis is not readily available.
引用
收藏
页码:4310 / 4316
页数:7
相关论文
共 50 条
  • [41] Detection of EGFR mutations with mutation-specific antibodies in primary lesions of non-small cell lung cancer
    Zhang, X.
    Yin, L.
    Yang, X.
    Yang, J.
    Zhou, Q.
    Xu, J.
    Xie, Z.
    An, S.
    Chen, S.
    Wang, R.
    Zhu, G.
    Gu, Y.
    Zhang, X.
    Wu, Y. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
    Sara Simonetti
    Miguel Angel Molina
    Cristina Queralt
    Itziar de Aguirre
    Clara Mayo
    Jordi Bertran-Alamillo
    José Javier Sanchez
    Jose Luis Gonzalez-Larriba
    Ulpiano Jimenez
    Dolores Isla
    Teresa Moran
    Santiago Viteri
    Carlos Camps
    Rosario Garcia-Campelo
    Bartomeu Massuti
    Susana Benlloch
    Santiago Ramon y Cajal
    Miquel Taron
    Rafael Rosell
    Journal of Translational Medicine, 8
  • [43] Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
    Simonetti, Sara
    Angel Molina, Miguel
    Queralt, Cristina
    de Aguirre, Itziar
    Mayo, Clara
    Bertran-Alamillo, Jordi
    Javier Sanchez, Jose
    Luis Gonzalez-Larriba, Jose
    Jimenez, Ulpiano
    Isla, Dolores
    Moran, Teresa
    Viteri, Santiago
    Camps, Carlos
    Garcia-Campelo, Rosario
    Massuti, Bartomeu
    Benlloch, Susana
    Ramon y Cajal, Santiago
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
  • [44] Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
    Gao, Xuejuan
    Zhao, Yanfeng
    Bao, Yi
    Yin, Wei
    Liu, Liyu
    Liu, Ruchuan
    Yu, Zhengquan
    Zhou, Xiao
    Shuai, Jianwei
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9621 - 9630
  • [45] Mutation-specific antibodies for the detection of EGFR mutation in non-small-cell lung cancer
    Yu, Jian
    Kane, Susan
    Li, Daigiang
    Benedettini, Elisa
    Haack, Herbert
    Smith, Bradly
    Gu, Tinglei
    Loda, Massimo
    Zhou, Xinmine
    Comb, Michael
    CANCER RESEARCH, 2009, 69
  • [46] Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
    Chen, Li-Yang
    Molina-Vila, Miguel A.
    Ruan, Sheng-Yuan
    Su, Kang-Yi
    Liao, Wei-Yu
    Yu, Kai-Lun
    Ho, Chao-Chi
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    Rosell, Rafael
    Yang, Pan-Chyr
    LUNG CANCER, 2016, 94 : 46 - 53
  • [47] The Performance of an L858R Mutation Specific EGFR Antibody in Non-Small Cell Lung Cancer Specimens
    Kyshtoobayeva, A.
    Bloom, K. J.
    LABORATORY INVESTIGATION, 2012, 92 : 480A - 481A
  • [48] The Performance of an L858R Mutation Specific EGFR Antibody in Non-Small Cell Lung Cancer Specimens
    Kyshtoobayeva, A.
    Bloom, K. J.
    MODERN PATHOLOGY, 2012, 25 : 480A - 481A
  • [49] A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer
    Yatabe, Yasushi
    Hida, Toyoaki
    Horio, Yoshitsugu
    Kosaka, Takayuki
    Takahashi, Takashi
    Mitsudomi, Tetsuya
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (03): : 335 - 341
  • [50] Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating EGFR Somatic Mutations
    Choi, Kuicheon
    Creighton, Chad J.
    Stivers, David
    Fujimoto, Nobukazu
    Kurie, Jonathan M.
    PLOS ONE, 2007, 2 (11):